|
Elena's Biotech Briefing
Silence Therapeutics’ rare blood cancer data raises the bar, Austria weighs a new life sciences growth fund, and Insilico plans interim earnings calls.
The top 10 stories from Tue Aug 11, 2026 06:49 AM to Wed Aug 12, 2026 06:45 AM
Generated August 12, 2026 at 6:45 AM
|
|
|
#1 Does China Reimburse Its Most Innovative Drugs? Published 2026-08-12 China’s basic medical insurance covers some of the country’s most innovative drugs, with solid tumors as the leading indication and Chinese companies dominating the covered products. Covered by: insights.citeline.com |
#2 New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration Published 2026-08-12 Laekna (2105.HK) said China’s NMPA CDE accepted its NDA for LAE002 (afuresertib) for treating patients, with details of the indication not provided in the available text. Covered by: prnewswire.com |
#3 With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development Published 2026-08-12 The article claims AI is increasingly used in drug development, including in pharma R&D and investment markets, to accelerate and reshape how new drugs are developed. Covered by: biospace.com |
#4 The State of Biotech 2026 Published 2026-08-11 The State of Biotech 2026 panel features John Maraganore of City Therapeutics and Jeremy Levin of Ovid Therapeutics, both with long leadership roles in RNAi and epilepsy drug development. Covered by: genengnews.com |
#5 Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M Published 2026-08-11 Eli Lilly agreed to pay up to $3.8 billion for vaccine-related biotech acquisitions, including a $2 billion upfront payment, while Infinimmune raised $75 million. Covered by: endpoints.news, biopharmadive.com |
#6 Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates Published 2026-08-11 Insilico Medicine announced it will hold conference calls to discuss its financial results for the six months ended, with dates to be determined. Covered by: prnewswire.com |
#7 Silence causes uproar in rare blood cancer space as data sets high bar for competitors Published 2026-08-11 Silence Therapeutics reported mid-stage trial success for its siRNA drug in polycythemia vera, raising expectations for similar therapies from Takeda, Agios, and Disc Medicine. Covered by: biospace.com |
#8 Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so Published 2026-08-11 Exelixis CEO Michael Morrissey reported 2025 results earlier this year, highlighting cabozantinib’s major role in funding the company and supporting its stock. Covered by: endpoints.news |
#9 Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO Published 2026-08-11 Lupin’s CEO said Europe may follow France’s biosimilar approach and that Germany’s reforms could affect both European and US biosimilar launch plans. Covered by: insights.citeline.com |
#10 Austria’s new growth fund could further bolster its dynamic biotech innovation economy Published 2026-08-11 Austria is considering a new national growth fund aimed at directing capital toward life sciences, leveraging its existing research hubs and nondilutive funding environment. Covered by: biospace.com |
